1-3 of 3
Karl M. Kilgore, PhD
Close
Sort by
Journal Articles

Cost and Healthcare Utilization in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real-World Analysis of Medicare Beneficiaries Receiving Chimeric Antigen Receptor T-Cell Vs. Autologous and Allogeneic Hematopoietic Cell Transplants

Iman Mohammadi, PhD, Anna G Purdum, Pharmd MS, Anny C Wong, PhD, Amy Schroeder, BPharm, Karl M Kilgore, PhD, Gunjan L. Shah, MDMS
Journal: Blood
Blood (2020) 136 (Supplement 1): 4.
https://doi.org/10.1182/blood-2020-134828
Published: 2020
Journal Articles

Burden of Illness and Outcomes in the 2nd Line Treatment of Large B-Cell Lymphoma: A Real-World Comparison of Medicare Beneficiaries with and without Stem Cell Transplants

Karl M Kilgore, PhD, Anny C Wong, PhD, Julia Thornton Snider, PhD, Paul Cheng, MDPhD, Amy Schroeder, BPharm, Iman Mohammadi, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-134812
Published: 2020
Journal Articles

Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs

Karl M. Kilgore, PhD, Iman Mohammadi, PhD, Amy Schroeder, BPharm, Christie Teigland, PhD, Anna Purdum, PharmD,MS, Gunjan L. Shah, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 793.
https://doi.org/10.1182/blood-2019-124364
Published: 2019